7 results match your criteria: "Hospital Universitario Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO)[Affiliation]"
Reply to P. de Boissieu et al.
J Clin Oncol
October 2024
David R. Spigel, MD, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Afshin Dowlati, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University Cleveland, OH; Yuanbin Chen, MD, Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI; Alejandro Navarro, MD, Hospital Universitario Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; James Chih-Hsin Yang, MD, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan; Goran Stojanovic, MD, Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia; Maria Jove, MD, PhD, Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, Spain; Patricia Rich, MD, Southeastern Regional Medical Center, Newnan, GA; Zoran G. Andric, MD, University Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia; Yi-Long Wu, MD, Guangdong Lung Cancer Institute, Guangzhou, China; Charles M. Rudin, MD PhD, Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY; Huanyu Chen, PhD, Ipsen, Cambridge, MA; Li Zhang, MPH, Ipsen, Cambridge, MA; Stanley Yeung, PharmD, Ipsen, Cambridge, MA; Fawzi Benzaghou, MD, Ipsen, Cambridge, MA; Luis Paz-Ares, MD, Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain; and Paul A. Bunn, MD, University of Colorado School of Medicine, Aurora, CO.
Article Synopsis
- The RESILIENT trial compared the effectiveness of liposomal irinotecan and topotecan as second-line treatments for small cell lung cancer (SCLC) after initial chemotherapy.
- No significant difference in overall survival (OS) was observed, with liposomal irinotecan showing a median OS of 7.9 months and topotecan at 8.3 months.
- Liposomal irinotecan had a higher objective response rate (ORR) of 44.1% compared to 21.6% for topotecan, but both treatments had similar safety profiles with grade ≥3 adverse events.
Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe.
Eur J Cancer
May 2023
Department of Radiation Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands. Electronic address:
Background: Local treatment improves the outcomes for oligometastatic disease (OMD, i.e. an intermediate state between locoregional and widespread disseminated disease).
View Article and Find Full Text PDFAn open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
Breast Cancer Res Treat
October 2022
Hospital Universitario Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Purpose: Abemaciclib, a CDK4 & 6 inhibitor, is indicated for advanced breast cancer treatment. Diarrhea is a frequently associated adverse event of abemaciclib. The study objective was to investigate if food intake impacts local gastrointestinal toxicity.
View Article and Find Full Text PDFDefinitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe.
Eur J Cancer
March 2022
Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands. Electronic address:
Background: Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking.
Objective: To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in Europe.
Material And Methods: European expert centers (n = 49) were requested to discuss 15 real-life cases in their MDT with at least a medical, surgical, and radiation oncologist present.
Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
Eur J Cancer
March 2021
Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain. Electronic address:
Introduction: Perioperative chemotherapy improves overall survival (OS) and disease-free survival (DFS) compared with surgery alone in patients with resectable gastric adenocarcinoma (GA) or gastro-oesophageal junction adenocarcinoma (GEJA). The addition of trastuzumab to chemotherapy improves outcomes in patients with HER2-positive advanced gastric cancer (GC), and we aimed to explore its role in the perioperative setting.
Material And Methods: This Spanish, multicentre, open-label phase II trial evaluated the efficacy and toxicity of perioperative capecitabine, oxaliplatin and trastuzumab (XELOX-T) in patients with HER2-positive resectable GA or GEJA.
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors.
Cancer Immunol Immunother
March 2019
Lung Cancer Unit, Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)-programmed cell death ligand-1 (PD-L1) axis have shown promising results in non-small cell lung cancer (NSCLC) patients, some of them with persistent responses to these agents that form a population of long-term survivors. Despite the variable definition of PD-L1 positivity in tumors, an association between expression and response has been reasonably consistent in advanced NSCLC. In addition, the clinical efficacy of ICIs seems to be related to the genomic landscape of the tumor in terms of mutational burden and clonal neoantigens.
View Article and Find Full Text PDF